March 27 (Reuters) - Pharma Mar SA PHMR.MC:
RECEIVES POSITIVE OPINION FROM THE EMA'S CHMP RECOMMENDING APPROVAL OF ZEPZELCA® (LURBINECTEDIN) IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ®) FOR TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
RECOMMENDATION IS BASED ON THE RESULTS OF THE IMFORTE PHASE 3 TRIAL
LURBINECTEDIN HAS ALSO RECEIVED POSITIVE OPINION FOR DESIGNATION AS ORPHAN DRUG IN SMALL CELL LUNG CANCER
PHASE 3 IMFORTE TRIAL, SPONSORED BY ROCHE IN COLLABORATION WITH JAZZ PHARMACEUTICALS
Source text